Abstract: A pharmaceutical composition comprising: (a) a pharmaceutically effective amount of meloxicam, or a pharmaceutically acceptable salt thereof; (b) a skin permeation enhancing agent selected from the group consisting of: (i) an amine of formula I wherein: R1, R2, and R3 are each independently an alkanolyl group with 1 to 24 C-atoms, in which one or more H-atoms are optionally substituted by —OH and/or one or more —CH2— groups are optionally substituted by —O—, or a polyoxyethylene group with 2 to 30 ethylene oxide units, and R2 and R3 are additionally independently H or a linear, branched, or cyclic alkyl group with 1 to 24 C-atoms, in which one or more —CH2— groups are optionally substituted by —CH?CH— and/or —O— and/or in which one or more H-atoms are optionally substituted by —OH, and (ii) an amide of formula II wherein: R4 and R5 are each independently a linear, branched, or cyclic alkyl group with 1 to 24 C-atoms, in which one or more —CH2— groups are optionally substituted by —CH?CH—and/or —O— an

Abstract: Oral pharmaceutical compositions comprising as pharmaceutically active compounds a combination of an antihistaminic-effective amount of epinastine or a pharmaceutically acceptable salt thereof, an anticholinergic amount of Belladonna alkaloids (Belladonna) or a pharmaceutically acceptable salt thereof, and of a decongestant-effective amount of pseudoephedrine or a pharmaceutically acceptable salt thereof. Optionally, the formulation includes methylephedrine (methylephrine) or a pharmaceutically acceptable salt thereof in a decongestant-effective amount. The composition further comprises suitable pharmaceutically acceptable carriers or excipients. Another aspect of the present invention relates methods of using such pharmaceutical compositions in the treatment of allergic diseases and/or disorders, in particular, seasonal allergic rhinitis and seasonal allergic conjunctivitis.